title: Management of recurrent epithelial ovarian cancer.
abstract: Epithelial ovarian cancer is the fifth most common cancer in women. It is usually diagnosed at an advanced stage and is the leading cause of death from gynecologic cancers in women. The overall survival rate at five years is 50% and its treatment is still poor. We need new treatments for patients with recurrent ovarian cancer who are incurable with current management. We review the effectiveness of new biological agents and morbidity and mortality of cytoreductive surgery. Since the hyperthermic increases the effectiveness of chemotherapy and the chance of survival, hyperthermic intraperitoneal chemotherapy has been proven to be a promising option, however it still requires further study to be the standard treatment.
authors.affiliation: Direction of Research, Juárez Hospital of Mexico, Mexico city, Mexico.
authors.forename: Víctor Manuel
authors.initials: VM
authors.lastname: Vargas-Hernández
authors.affiliation: Direction of Research, Juárez Hospital of Mexico, Mexico city, Mexico.
authors.forename: Mario Adan
authors.initials: MA
authors.lastname: Moreno-Eutimio
authors.affiliation: Direction of Research, Juárez Hospital of Mexico, Mexico city, Mexico.
authors.forename: Gustavo
authors.initials: G
authors.lastname: Acosta-Altamirano
authors.affiliation: Direction of Research, Juárez Hospital of Mexico, Mexico city, Mexico.
authors.forename: Víctor Manuel
authors.initials: VM
authors.lastname: Vargas-Aguilar
keywords: Epithelial ovarian cancer; biological agents; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; morbidity and mortality